Alexion Pharmaceuticals (ALXN) Stock Price, News & Analysis

Company Overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $182.50 to $182.50
• 50-Day Range: $179.45 to $186.61
• 52-Week Range: $99.91 to $187.45
• Volume: 10 shs
• Average Volume: 3.31 million shs
• Market Capitalization: $40.34 billion
• P/E Ratio: 59.64
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Alexion Pharmaceuticals Stock Analysis - MarketRank™

Alexion Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 638th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Alexion Pharmaceuticals.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 6.12%

Earnings Growth

Earnings for Alexion Pharmaceuticals are expected to grow by 6.12% in the coming year, from $13.08 to $13.88 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alexion Pharmaceuticals is 59.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alexion Pharmaceuticals is 59.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 90.13.

Price to Earnings Growth Ratio

Alexion Pharmaceuticals has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Alexion Pharmaceuticals has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ALXN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alexion Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Alexion Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -1.88

Short Interest

There is no current short interest data available for ALXN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Alexion Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alexion Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.03% of the stock of Alexion Pharmaceuticals is held by insiders.

Percentage Held by Institutions

82.94% of the stock of Alexion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALXN Stock Analysis - Frequently Asked Questions

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its earnings results on Thursday, April, 29th. The biopharmaceutical company reported $3.52 EPS for the quarter, topping the consensus estimate of $3.16 by $0.36. The business's revenue was up 13.3% on a year-over-year basis.

Does Alexion Pharmaceuticals have any subsidiaries?

The following companies are subsidiaries of Alexion Pharmaceuticals: Portola Pharmaceuticals Inc., Achillion Pharmaceuticals, Syntimmune, Wilson Therapeutics, Synageva BioPharma Corp., Enobia Pharma Corp., Taligen Therapeutics Inc., and others.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alexion Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Tesla (TSLA), Netflix (NFLX), Gilead Sciences (GILD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 4/29/2021
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALXN
• CUSIP: 01535110
• CIK: 899866
• Web: www.alexion.com
• Phone: 475-230-2596
• Fax: N/A
• Employees: 3,837
• Year Founded: 1992

Profitability

• EPS (Most Recent Fiscal Year): $11.60
• Trailing P/E Ratio: 59.64
• Forward P/E Ratio: 13.95
• P/E Growth: 0.93
• Net Income: $603.40 million
• Net Margins: 10.89%
• Pretax Margin: N/A
• Return on Equity: 23.43%
• Return on Assets: 15.06%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 4.52
• Quick Ratio: 3.96

Sales & Book Value

• Annual Sales: $6.07 billion
• Price / Sales: 6.65
• Cash Flow: $22.81 per share
• Price / Cash Flow: 8.00
• Book Value: $53.24 per share
• Price / Book: 3.43

Miscellaneous

• Outstanding Shares: 221,019,000
• Free Float: N/A
• Market Cap: $40.34 billion
• Optionable: Optionable
• Beta: 1.25